Application of Novel Hollow Carbon Nanosphere Drug-Loading System in Chemotherapy of Esophageal Squamous Cell Carcinoma.

Abstract

With the continuous improvement of carbon nanotube synthesis and purification technology and the continuous improvement of carbon nanotube dispersion technology, carbon nanotubes have played an increasingly important role in the treatment of malignant tumours. One of the hot spots. Compared with other carbon nanotube materials, the carbon nanosphere drug loading system is more suitable for loading hydrophobic drugs, and the drug loading capacity is higher than other one-dimensional two-dimensional carbon nano-materials. In addition, carbon nanospheres of a suitable size are more easily absorbed by tumour cells and can carry a large amount of drugs for transport in the blood. And the pore structure of the carbon nanosphere is adjustable, and the drug release can be controlled by adjusting the pore size, and the pore diameter is generally less than 10 nm to prevent the drug from being released in advance. Esophageal cancer is one of the most frequently occurring malignancies in China, and the incidence of esophageal cancer ranks 8th in the world. Palliative chemotherapy is t he main treatment method for patients with advanced esophageal cancer. Simultaneous chemoradiotherapy has relatively obvious advantages in improving the survival rate of patients. It is of great significance to study the application of carbon nanosphere drug-loading system in chemoradiotherapy for esophageal squamous cell carcinoma. Therefore, in this study under the hydrothermal method, which is one of the commonly used methods for the synthesis of hollow carbon nanospheres, carboxymethyl chitosan was used as a carbon precursor, and the targeted drug erlotinib was loaded with carbon nanospheres. A new hollow nano-carbon sphere drug-loading system (HNCSDLS) was prepared and related characterizations were carried out. At the same time, the morphology, properties, in vitro and in vivo toxicity, bio-distribution, and anti-tumour activity of HNCSDLS were also studied in this study using scanning electron microscopy flow cytometry, laser confocal, spectrometer, cell proliferation experiment, and in vivo fluorescence imaging experiment Detection. The results of this study indicate that HNCSDLS has high biocom-patibility and stability, can be quickly distributed in the cytoplasm, and avoids lysosomal clearance. It can effectively deliver erlotinib to the tumour site, extend the drug s in vivo circulation time, inhibit tumour growth, reduce the toxicity of erlotinib to heart and kidney tissues, and increase its antitumor activity.